Jonathan Auerbach’s Hound Partners has finally thrown in the towel on Valeant Pharmaceuticals International, a stock that boosted the firm’s coffers spectacularly in recent years before tanking its portfolio over the past ten months.
Michael Nagle
Jonathan Auerbach’s Hound Partners has finally thrown in the towel on Valeant Pharmaceuticals International, a stock that boosted the firm’s coffers spectacularly in recent years before tanking its portfolio over the past ten months.
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.
